Insmed stated that it is focused on the development and commercialization of ARIKACE (liposomal amikacin for inhalation) for at least two identified orphan patient
populations: cystic fibrosis (CF) patients with Pseudomonas aeruginosa lung infections and patients with non-tuberculous mycobacteria (NTM) lung infections.
com, a nationwide, Patient-Centered Health Management[R] organization dedicated to improving the quality of life for people with orphan, Ultra Orphan and chronic genetic disorders, will present its fourth annual conference, "Addressing the Needs of the Ultra Orphan Patient
Populations by Creating and Measuring Value: Strategies for Delivering Outcomes and Value for Patients, Physicians, Payers and Manufacturers," Sept.
Insmed Incorporated is a biopharmaceutical company dedicated to improving the lives of patients battling serious orphan lung diseases through the development and commercialization of novel, targeted inhalation therapies in orphan patient
populations with critical unmet needs.
In bringing ATryn to market, we remain committed to addressing the medical needs of orphan patient
The targeted orphan patient
population is estimated at 30,000-50,000 patients in the United States.
Orphan Drug Designation is a necessary first step towards gaining regulatory approval for any product used to treat Orphan patient
Obtaining Orphan Designation from the FDA is a necessary first step towards gaining regulatory approval for any new product designed to address clinical needs in Orphan patient
The number of orphan patients
has continued to increase in recent years, as family practitioners forgo hospital privileges to concentrate on their office-based practices.
Highlighting the role of specialty pharmaceuticals as the fastest growing segment of the prescription drug market in the United States, the recent Second Annual Ultra Orphan Conference: "Emerging Commercialization Strategies for Addressing the Needs of Ultra Orphan Patients
-- Accelerate Product Launch and Profitability by Building Regulatory Requirements into Distribution," offered stakeholders insights into industry trends, explained the impact of healthcare reform, and identified opportunities to turn Risk Evaluation and Mitigation Strategies (REMS) into a competitive advantage.
com), presents its Second Annual Ultra Orphan Conference: "Emerging Commercialization Strategies for Addressing the Needs of Ultra Orphan Patients
-- Accelerate Product Launch and Profitability by Building Regulatory Requirements into Distribution," August 24-26, 2009, Ameristar Casino & Hotel, St.